Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …

During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

Purpose Although programmed death (PD)-1 pathway inhibitors are now used in nearly all
patients with advanced non–small-cell lung cancer (NSCLC), the large number of patients …

Immune checkpoint inhibitors, including those targeting the programmed cell death
1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are …

Immune checkpoint inhibitors have emerged as a remarkable treatment option for diverse
cancer types. However, a significant number of patients on checkpoint inhibitors develop …

Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …

Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically
been a relevant issue. In addition, targeted therapies and biological molecules can also …

PURPOSE Antibiotic exposure before immune checkpoint inhibitor (ICI) treatment can
negatively affect outcomes through alteration in the gut microbiome, but large-scale …